348 related articles for article (PubMed ID: 32015035)
21. Outcome of bloodstream infections among spinal cord injury patients and impact of multidrug-resistant organisms.
Saliba M; Saadeh D; Bouchand F; Davido B; Duran C; Clair B; Lawrence C; Annane D; Denys P; Salomon J; Bernard L; Dinh A
Spinal Cord; 2017 Feb; 55(2):148-154. PubMed ID: 27995941
[TBL] [Abstract][Full Text] [Related]
22. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.
Tam VH; Rogers CA; Chang KT; Weston JS; Caeiro JP; Garey KW
Antimicrob Agents Chemother; 2010 Sep; 54(9):3717-22. PubMed ID: 20585122
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
[TBL] [Abstract][Full Text] [Related]
24. Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
Tumbarello M; Raffaelli F; Peghin M; Losito AR; Chirico L; Giuliano G; Spanu T; Sartor A; Fiori B; Bassetti M
Int J Antimicrob Agents; 2020 Apr; 55(4):105900. PubMed ID: 31931150
[TBL] [Abstract][Full Text] [Related]
25. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
26. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.
Yang MA; Lee J; Choi EH; Lee HJ
J Korean Med Sci; 2011 May; 26(5):612-8. PubMed ID: 21532850
[TBL] [Abstract][Full Text] [Related]
27. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.
Endimiani A; Luzzaro F; Pini B; Amicosante G; Rossolini GM; Toniolo AQ
BMC Infect Dis; 2006 Mar; 6():52. PubMed ID: 16542460
[TBL] [Abstract][Full Text] [Related]
28. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
31. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.
Tofas P; Samarkos M; Piperaki ET; Kosmidis C; Triantafyllopoulou ID; Kotsopoulou M; Pantazatou A; Perlorentzou S; Poulli A; Vagia M; Daikos GL
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):335-341. PubMed ID: 28529091
[TBL] [Abstract][Full Text] [Related]
32. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
[TBL] [Abstract][Full Text] [Related]
33. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
34. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.
Fernández-Cruz A; Alba N; Semiglia-Chong MA; Padilla B; Rodríguez-Macías G; Kwon M; Cercenado E; Chamorro-de-Vega E; Machado M; Pérez-Lago L; García de Viedma D; Díez Martín JL; Muñoz P
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530598
[TBL] [Abstract][Full Text] [Related]
35. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
[TBL] [Abstract][Full Text] [Related]
36. Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance.
Martinez-Nadal G; Puerta-Alcalde P; Gudiol C; Cardozo C; Albasanz-Puig A; Marco F; Laporte-Amargós J; Moreno-García E; Domingo-Doménech E; Chumbita M; Martínez JA; Soriano A; Carratalà J; Garcia-Vidal C
Clin Infect Dis; 2020 Mar; 70(6):1068-1074. PubMed ID: 31321410
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.
Sader HS; Castanheira M; Duncan LR; Flamm RK
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):69-74. PubMed ID: 29789189
[TBL] [Abstract][Full Text] [Related]
38. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
Peña C; Suarez C; Gozalo M; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2012 Mar; 56(3):1265-72. PubMed ID: 22155832
[TBL] [Abstract][Full Text] [Related]
39. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
40. Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes.
Sood P; Seth T; Kapil A; Sharma V; Dayama A; Sharma S; Kumar S; Singh AK; Mishra P; Mahapatra M
J Indian Med Assoc; 2012 Jul; 110(7):439-44. PubMed ID: 23520666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
